Sangtaeck Lim, MPH, is affiliated with Teva Branded Pharmaceutical Products R&D, Inc., Global Health Economics and Outcomes Research in West Chester, Pennsylvania. Lim has published research focused on schizophrenia and schizoaffective disorders, specifically examining treatment pathways and factors influencing the initiation of atypical long-acting injectable antipsychotic agents in early-phase schizophrenia. Lim's work includes collaboration with co-authors such as John M. Kane and Jose M. Rubio.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
